Interferon-γ expression is an independent prognostic factor in ovarian cancer

被引:73
作者
Marth, C
Fiegl, H
Zeimet, AG
Müller-Holzner, E
Deibl, M
Doppler, W
Daxenbichler, G
机构
[1] Univ Innsbruck, Hosp Med, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria
[2] Univ Innsbruck, Hosp Med, Dept Biostat & Documentat, A-6020 Innsbruck, Austria
[3] Innsbruck Med Univ, Dept Med Biochem, Innsbruck, Austria
关键词
interferon-gamma; ovarian cancer; cancer immunology; chemotherapy;
D O I
10.1016/j.ajog.2004.05.007
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: Epithelial ovarian cancer prognosis is improved by the presence of intratumoral CD3(+) T cells; which are known to produce interferon-gamma. We therefore speculated that interferon-gamma expression in ovarian cancer-infiltrating T-lymphocytes might cause better prognosis. Patients and methods: Reverse transcriptase polymerase chain reaction was performed to measure the expression of interferon-gamma and other related genes in normal ovaries (n = 19) and in ovarian cancer specimens (n = 99). Median follow-up of patients was 5.8 years. Results: Interferon-gamma and CD-3 expression did not significantly differ in normal and malignant tissue. Patients with high levels of interferon-gamma expression had significantly longer progression-free and overall survival. Median time to progression was 10 and 29 months for patients with low and high interferon-gamma expression, respectively (P = .039). Corresponding survival times were 29 and 44 months (P < .032). Application of multivariate Cox regression analysis showed interferon-gamma expression to be an independent prognostic factor for progression-free and overall survival. Conclusion: Elevated interferon-gamma expression correlates with improved clinical outcome in patients with ovarian cancer. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1598 / 1605
页数:8
相关论文
共 28 条
[1]   Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction [J].
Bièche, I ;
Franc, B ;
Vidaud, D ;
Vidaud, M ;
Lidereau, R .
THYROID, 2001, 11 (02) :147-152
[2]   Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma [J].
Bromberg, JF ;
Horvath, CM ;
Wen, ZL ;
Schreiber, RD ;
Darnell, JE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) :7673-7678
[3]   Cytotoxic response of ovarian cancer cell lines to IFN-γ is associated with sustained induction of IRF-1 and p21 mRNA [J].
Burke, F ;
Smith, PD ;
Crompton, MR ;
Upton, C ;
Balkwill, FR .
BRITISH JOURNAL OF CANCER, 1999, 80 (08) :1236-1244
[4]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[5]   Effector pathways regulating T cell activation [J].
Favero, J ;
Lafont, V .
BIOCHEMICAL PHARMACOLOGY, 1998, 56 (12) :1539-1547
[6]   Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer [J].
Fornier, M ;
Esteva, FJ ;
Seidman, AD .
SEMINARS IN ONCOLOGY, 2000, 27 (06) :38-45
[7]   Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-κB [J].
Ganster, RW ;
Taylor, BS ;
Shao, LF ;
Geller, DA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) :8638-8643
[8]   Clonal expansion of T cells that are specific for autologous ovarian tumor among tumor-infiltrating T cells in humans1 [J].
Hayashi, K ;
Yonamine, K ;
Masuko-Hongo, K ;
Iida, T ;
Yamamoto, K ;
Nishioka, K ;
Kato, T .
GYNECOLOGIC ONCOLOGY, 1999, 74 (01) :86-92
[9]   The antiviral state induced by alpha interferon and gamma interferon requires transcriptionally active Stat1 protein [J].
Horvath, CM ;
Darnell, JE .
JOURNAL OF VIROLOGY, 1996, 70 (01) :647-650
[10]   A positive regulatory role for suppressor of cytokine signaling 1 in IFN-γ-induced MHC class II expression in fibroblasts [J].
Ilangumaran, S ;
Finan, D ;
La Rose, J ;
Raine, J ;
Silverstein, A ;
De Sepulveda, P ;
Rottapel, R .
JOURNAL OF IMMUNOLOGY, 2002, 169 (09) :5010-5020